Quarterly ResultMay 14, 2026, 08:02 AM
Chemomab Q1 Net Loss $1.8M; Nebokitug Shows IBD Benefit in PSC
AI Summary
Chemomab Therapeutics announced its first quarter 2026 financial results, reporting a net loss of $1.8 million. The company also provided a corporate update, highlighting new clinical and translational data for nebokitug presented at Digestive Disease Week 2026 and upcoming presentations at EASL Congress 2026. These studies further confirm nebokitug's disease-modifying potential in Primary Sclerosing Cholangitis (PSC) and suggest possible additional benefits for PSC patients with co-existing Inflammatory Bowel Disease (IBD). Chemomab continues to pursue multiple partnering options for nebokitug.
Key Highlights
- Cash, cash equivalents, and short-term bank deposits were $8.0 million as of March 31, 2026.
- The company's cash runway is expected to fund operations through the end of the first quarter of 2027.
- Net loss for the first quarter of 2026 was $1.8 million, compared to $3.3 million for Q1 2025.
- Research and Development (R&D) expenses decreased to $0.9 million in Q1 2026 from $2.5 million in Q1 2025.
- General and Administrative (G&A) expenses were $0.9 million in Q1 2026, down from $1.0 million in Q1 2025.
- New clinical data for nebokitug presented at DDW 2026 and EASL 2026 showed benefits in PSC and co-existing IBD.
- An AI/machine learning model successfully identified composite efficacy improvement in nebokitug-treated PSC patients.
- Nebokitug treatment was associated with statistically significant and dose-dependent reductions in PSC-related fibrotic and immune proteins.